# Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

> **NCT00808678** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 90 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ABT-143
- **DRUG:** ABT-335
- **DRUG:** rosuvastatin

## Key facts

- **NCT ID:** NCT00808678
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808678, "Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00808678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*